Authum Investment & Infrastructure Limited (AIIL) has entered into a Commercial Transaction agreement on 13 June 2025 with Devicam Capital LLP and Pronomz Ventures LLP.

• Under this agreement, AIIL will acquire 39,27,000 shares of OneSource Specialty Pharma Limited (NSE: ONESOURCE | BSE: 544292).
• This acquisition will result in AIIL holding 3.43% of the voting rights in OneSource Specialty on a fully diluted basis.
• OneSource Specialty Pharma Limited, a pharmaceuticals company, had a Net Worth of ₹ 5,880 Crores and a Turnover of ₹ 1,444.8 Crores as of March 31, 2025.
• The company, incorporated on 12 June 2007, was formerly known as Stelis Biopharma Limited and rebranded in February 2024 as India’s first specialty pharma pure-play Contract Development and Manufacturing Organization (CDMO).
• Its turnover for the last three fiscal years was: FY 22-23: ₹ 41.07 Crores; FY 23-24: ₹ 171.90 Crores; FY 24-25: ₹ 1,444.8 Crores.
• The acquisition is part of a Commercial Transaction, and its fair market value, based on NSE price on 13 June 2025, is aggregating to ₹ 2,028.
• No governmental or regulatory approvals are required for this acquisition, which was completed on 13 June 2025.